New York, May 17, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Industry" - https://www.reportlinker.com/p06032349/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market to Reach $54 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics estimated at US$24.6 Billion in the year 2022, is projected to reach a revised size of US$54 Billion by 2030, growing at aCAGR of 10.3% over the period 2022-2030. Targeted Therapy, one of the segments analyzed in the report, is projected to record 11.7% CAGR and reach US$31.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Immunotherapy segment is readjusted to a revised 8.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $6.7 Billion, While China is Forecast to Grow at 16.5% CAGR
The Non-Small Cell Lung Cancer (NSCLC) Therapeutics market in the U.S. is estimated at US$6.7 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$14.1 Billion by the year 2030 trailing a CAGR of 16.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 8.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.
Select Competitors (Total 34 Featured)
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene Corp.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Genentech Inc.
- GlaxoSmithKline plc
- Novartis
- Pfizer Inc.
- Roche Holding AG
- Sun Pharmaceutical Industries Ltd.
Read the full report: https://www.reportlinker.com/p06032349/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Key
Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Non-Small Cell Lung Cancer (NSCLC) Therapeutics
Market Analysis of Annual Sales in US$ Million for Years 2014
through 2030
Table 2: World Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2022 through 2030 and
% CAGR
Table 3: World Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2014 through 2021 and % CAGR
Table 4: World 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2014, 2023 & 2030
Table 5: World Recent Past, Current & Future Analysis for
Targeted Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 6: World Historic Review for Targeted Therapy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 7: World 16-Year Perspective for Targeted Therapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 8: World Recent Past, Current & Future Analysis for
Immunotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 9: World Historic Review for Immunotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 10: World 16-Year Perspective for Immunotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 11: World Recent Past, Current & Future Analysis for
Chemotherapy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2022 through 2030 and % CAGR
Table 12: World Historic Review for Chemotherapy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 13: World 16-Year Perspective for Chemotherapy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 14: World Recent Past, Current & Future Analysis for
Adenocarcinoma by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 15: World Historic Review for Adenocarcinoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 16: World 16-Year Perspective for Adenocarcinoma by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 17: World Recent Past, Current & Future Analysis for
Squamous Cell Carcinoma by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 18: World Historic Review for Squamous Cell Carcinoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 19: World 16-Year Perspective for Squamous Cell Carcinoma
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
Table 20: World Recent Past, Current & Future Analysis for
Large Cell Carcinoma by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 21: World Historic Review for Large Cell Carcinoma by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 22: World 16-Year Perspective for Large Cell Carcinoma by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in the United
States for 2023 (E)
Table 23: USA Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 24: USA Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 25: USA 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2014, 2023 & 2030
Table 26: USA Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 27: USA Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 28: USA 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
CANADA
Table 29: Canada Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 30: Canada Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 31: Canada 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2014, 2023 & 2030
Table 32: Canada Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 33: Canada Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 34: Canada 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
JAPAN
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in Japan for
2023 (E)
Table 35: Japan Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 36: Japan Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 37: Japan 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2014, 2023 & 2030
Table 38: Japan Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 39: Japan Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 40: Japan 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
CHINA
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in China for
2023 (E)
Table 41: China Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 42: China Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 43: China 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2014, 2023 & 2030
Table 44: China Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 45: China Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 46: China 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
EUROPE
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in Europe for
2023 (E)
Table 47: Europe Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2022 through 2030 and % CAGR
Table 48: Europe Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 49: Europe 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
Table 50: Europe Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 51: Europe Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 52: Europe 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2014, 2023 & 2030
Table 53: Europe Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 54: Europe Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 55: Europe 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
FRANCE
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in France for
2023 (E)
Table 56: France Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 57: France Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 58: France 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2014, 2023 & 2030
Table 59: France Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 60: France Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 61: France 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
GERMANY
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in Germany for
2023 (E)
Table 62: Germany Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 63: Germany Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 64: Germany 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2014, 2023 & 2030
Table 65: Germany Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 66: Germany Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 67: Germany 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
ITALY
Table 68: Italy Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 69: Italy Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 70: Italy 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2014, 2023 & 2030
Table 71: Italy Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 72: Italy Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 73: Italy 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
UNITED KINGDOM
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in the United
Kingdom for 2023 (E)
Table 74: UK Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 75: UK Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 76: UK 16-Year Perspective for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value
Sales for Targeted Therapy, Immunotherapy and Chemotherapy for
the Years 2014, 2023 & 2030
Table 77: UK Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 78: UK Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 79: UK 16-Year Perspective for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Percentage Breakdown of
Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
SPAIN
Table 80: Spain Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 81: Spain Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 82: Spain 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2014, 2023 & 2030
Table 83: Spain Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 84: Spain Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 85: Spain 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
RUSSIA
Table 86: Russia Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 87: Russia Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 88: Russia 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Chemotherapy for the Years 2014, 2023 & 2030
Table 89: Russia Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 90: Russia Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous
Cell Carcinoma and Large Cell Carcinoma Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2014 through
2021 and % CAGR
Table 91: Russia 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown
of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and
Large Cell Carcinoma for the Years 2014, 2023 & 2030
REST OF EUROPE
Table 92: Rest of Europe Recent Past, Current & Future Analysis
for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 93: Rest of Europe Historic Review for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 94: Rest of Europe 16-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage
Breakdown of Value Sales for Targeted Therapy, Immunotherapy
and Chemotherapy for the Years 2014, 2023 & 2030
Table 95: Rest of Europe Recent Past, Current & Future Analysis
for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by
Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large
Cell Carcinoma - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 96: Rest of Europe Historic Review for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 97: Rest of Europe 16-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Percentage
Breakdown of Value Sales for Adenocarcinoma, Squamous Cell
Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 &
2030
ASIA-PACIFIC
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in Asia-
Pacific for 2023 (E)
Table 98: Asia-Pacific Recent Past, Current & Future Analysis
for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by
Geographic Region - Australia, India, South Korea and Rest of
Asia-Pacific Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2022 through 2030 and % CAGR
Table 99: Asia-Pacific Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 100: Asia-Pacific 16-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Geographic Region -
Percentage Breakdown of Value Sales for Australia, India, South
Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 &
2030
Table 101: Asia-Pacific Recent Past, Current & Future Analysis
for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy -
Independent Analysis of Annual Sales in US$ Million for the
Years 2022 through 2030 and % CAGR
Table 102: Asia-Pacific Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 103: Asia-Pacific 16-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage
Breakdown of Value Sales for Targeted Therapy, Immunotherapy
and Chemotherapy for the Years 2014, 2023 & 2030
Table 104: Asia-Pacific Recent Past, Current & Future Analysis
for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by
Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large
Cell Carcinoma - Independent Analysis of Annual Sales in US$
Million for the Years 2022 through 2030 and % CAGR
Table 105: Asia-Pacific Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 106: Asia-Pacific 16-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Percentage
Breakdown of Value Sales for Adenocarcinoma, Squamous Cell
Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 &
2030
AUSTRALIA
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in Australia
for 2023 (E)
Table 107: Australia Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 108: Australia Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 109: Australia 16-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage
Breakdown of Value Sales for Targeted Therapy, Immunotherapy
and Chemotherapy for the Years 2014, 2023 & 2030
Table 110: Australia Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology -
Adenocarcinoma, Squamous Cell Carcinoma and Large Cell
Carcinoma - Independent Analysis of Annual Sales in US$ Million
for the Years 2022 through 2030 and % CAGR
Table 111: Australia Historic Review for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma,
Squamous Cell Carcinoma and Large Cell Carcinoma Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2014 through 2021 and % CAGR
Table 112: Australia 16-Year Perspective for Non-Small Cell
Lung Cancer (NSCLC) Therapeutics by Histology - Percentage
Breakdown of Value Sales for Adenocarcinoma, Squamous Cell
Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 &
2030
INDIA
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence -
Strong/Active/Niche/Trivial - Key Competitors in India for
2023 (E)
Table 113: India Recent Past, Current & Future Analysis for
Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy -
Targeted Therapy, Immunotherapy and Chemotherapy - Independent
Analysis of Annual Sales in US$ Million for the Years 2022
through 2030 and % CAGR
Table 114: India Historic Review for Non-Small Cell Lung Cancer
(NSCLC) Therapeutics by Therapy - Targeted Therapy,
Immunotherapy and Chemotherapy Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2014 through 2021 and
% CAGR
Table 115: India 16-Year Perspective for Non-Small Cell Lung
Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown
of Value Sales for Targeted Therapy, Immunotherapy and
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032349/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
